By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Argos Therapeutics, Inc. (Formerly Merix Bioscience) 

4233 Technology Drive

Durham  North Carolina  27704  U.S.A.
Phone: 919-287-6300 Fax: 919-287-6301




Duke University  Exclusive license to the RNA based vaccine technology.

Rockefeller University  Exclusive worldwide rights to technology developed at Rockefeller relating to generation of dendritic cells.

Baylor University  Clinical and preclinical research in Lupus.

Kirin Brewery Co., Ltd.  The companies will collaborate to develop and commercialize dendritic cell vaccines, initially in the areas of cancer and infectious diseases.

Erlangen University  Clinical and preclinical research in Melanoma.

Company News
Argos (ARGS) Announces Closing Of $6 Million Secured Convertible Note Financing 6/22/2017 10:46:04 AM
Argos (ARGS) Announces $6 Million Secured Convertible Note Financing 6/16/2017 8:24:22 AM
Argos (ARGS) Provides Update On Its ADAPT Trial Following Meeting With FDA 5/10/2017 9:01:56 AM
Argos (ARGS) Reports Interim Results Of The ADAPT Trial And Provides Perspective On Decision To Continue The Trial 4/19/2017 10:31:39 AM
Argos (ARGS) Cuts Staff by 38% After Devastating Phase III News 3/10/2017 6:26:11 AM
Committee Recommends Discontinuation of Argos (ARGS)' Phase III Renal Cell Carcinoma Study 2/22/2017 6:54:42 AM
Argos (ARGS) Announces Proposed Public Offering Of Common Stock And Warrants 7/28/2016 8:03:07 AM
Argos (ARGS) Slashes 13% of Workforce to Complete a Phase III Study Under Budget, COO Resigns 4/21/2016 7:13:59 AM
Argos Therapeutics, Inc. (ARGS) Release: Independent Data Monitoring Committee Recommends Continuation Of ADAPT Phase III Clinical Trial Of AGS-003 For Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis 12/10/2015 7:12:33 AM
Argos Therapeutics, Inc. (ARGS) To Participate In The ROTH Immuno-Oncology Corporate Access Day 12/9/2015 7:35:47 AM